Chapter 7.1 - Design of liposome-based drug carriers: from basic research to application as approved drugs. In: Papahadjopoulos DDL (ed.) Medical applications of liposomes. Amsterdam: Elsevier Science B.V, 1998, pp.545-565.Barenholz, Y. Design of liposome-based drug carriers: from basic ...
PARIS, FRANCE, 13 February 2024– Ipsen (Euronext: IPN; ADR: IPSEY) announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental new drug application for Onivyde®(irinotecan liposome injection) plus oxaliplati...
Considering whether an FDA-regulated product involves the application of nanotechnology; Drug products, including biological products, that contain nanomaterials guidance for industry (draft); Guidance for industry: liposome drug products chemistry, manufacturing, and controls; human pharmacokinetics and bioavai...
However, although 2nd-generation (1980–2010) DDSs (e.g., liposomes, nanoparticle, microsphere and gene delivery) attracted lots of attention, there have been very limited products in the markets until now [7–9]. The liposome Doxil® emerged as the first nanodrug in 1995 [13]. Abraxane...